Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human

Cited:

Human, Mouse, Transgenic Mouse

Applications

Validated:

Immunohistochemistry, Western Blot

Cited:

Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Western Blot, Flow Cytometry, Immunocytochemistry, Immunoprecipitation

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG
View all VEGFR3/Flt-4 Primary Antibodies »

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human VEGFR3/Flt-4
Tyr25-Ile776
Accession # P35916

Specificity

Detects human VEGFR3/Flt-4 in direct ELISAs and Western blots. In Western blots, approximately 15% cross-reactivity with recombinant mouse VEGFR3 is observed and less than 2% cross-reactivity with recombinant human VEGFR1 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Human VEGFR3/Flt-4 Antibody

VEGFR3/Flt-4 antibody in Human Cervical Squamous Metaplasia by Immunohistochemistry (IHC-P).

VEGFR3/Flt‑4 in Human Cervical Squamous Metaplasia.

VEGFR3/Flt-4 was detected in immersion fixed paraffin-embedded sections of human cervical squamous metaplasia using Human VEGFR3/Flt-4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF349) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Detection of Human VEGFR3/Flt-4 by Western Blot

Detection of Human VEGFR3/Flt-4 by Western Blot

TGF-beta 1, -beta 2 and -beta 3 reduce lymphatic marker expression in LECs.Primary human LECs were treated with 10, 20 or 30 ng/ml TGF-beta 1, -beta 2 and -beta 3 for 72 hours (a) or 100 hours (b). Untreated cells served as a control. Lysates were prepared and analysed by Western blot using antibodies specific for Lyve-1, Prox-1, VEGFR-3 or vimentin. Vinculin served as loading control. The experiment was performed twice with equivalent results. For densitometry evaluation, protein bands were analysed using the software ImageJ. Bands for the Prox-1, Lyve-1, vimentin and VEGFR-3 proteins were normalized to the corresponding loading control and are displayed as the expression level relative to the untreated control samples. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0162221), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human VEGFR3/Flt-4 by Immunocytochemistry/ Immunofluorescence

Detection of Human VEGFR3/Flt-4 by Immunocytochemistry/ Immunofluorescence

Direct interaction between PI3K p85 and VEGFR-3.A, LEC whole cell lysate was immunoprecipitated with anti-PI3K or isotype control IgG followed by Western blotting of phospho-tyrosine (p-Tyr), VEGFR-3 or PI3K. LECs were treated with vehicle control (serum-free media ‘0′), IgG control, VEGF-C (100 ng/ml, C) or VEGF-A (100 ng/ml, A) ligand for 15 minutes. Control untreated LEC whole cell lysate is indicate by ‘WCL’ and Jurkat cell lysate served as a positive control (Jurkat). B, Detection of VEGFR-3/phospho-PI3K complexes (red spots) in vitro in LECs grown in absence (B, upper left panel) or presence (B, upper middle panel) of VEGF-C (100 ng/ml) for 15 minutes; CD31 staining (green); DAPI (blue); isotype IgG control in PLA (B, upper right panel); quantification of VEGFR-3/phospho-PI3K and VEGFR-3/total-PI3K PLA signals using Olink Imaging Software (B, lower panel). Data shown as mean±s.e.m. **P<0.01 using t-test analysis. n = 3. Bar = 50 µm. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0039558), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human VEGFR3/Flt-4 by Immunocytochemistry/ Immunofluorescence

Detection of Human VEGFR3/Flt-4 by Immunocytochemistry/ Immunofluorescence

Direct interaction between PI3K p85 and VEGFR-3.A, LEC whole cell lysate was immunoprecipitated with anti-PI3K or isotype control IgG followed by Western blotting of phospho-tyrosine (p-Tyr), VEGFR-3 or PI3K. LECs were treated with vehicle control (serum-free media ‘0′), IgG control, VEGF-C (100 ng/ml, C) or VEGF-A (100 ng/ml, A) ligand for 15 minutes. Control untreated LEC whole cell lysate is indicate by ‘WCL’ and Jurkat cell lysate served as a positive control (Jurkat). B, Detection of VEGFR-3/phospho-PI3K complexes (red spots) in vitro in LECs grown in absence (B, upper left panel) or presence (B, upper middle panel) of VEGF-C (100 ng/ml) for 15 minutes; CD31 staining (green); DAPI (blue); isotype IgG control in PLA (B, upper right panel); quantification of VEGFR-3/phospho-PI3K and VEGFR-3/total-PI3K PLA signals using Olink Imaging Software (B, lower panel). Data shown as mean±s.e.m. **P<0.01 using t-test analysis. n = 3. Bar = 50 µm. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0039558), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of VEGFR3/Flt-4 by Western Blot

Detection of VEGFR3/Flt-4 by Western Blot

VEGF-C induces LEC tube formation.A, Prostatic LEC tube length at 4.5 hours post VEGF-C treatment was quantified using ImageJ. VEGF-C significantly increased the number of tubes formed compared to vehicle control. Data expressed as mean±s.e.m., n = 3, ***P<0.001 using One-way ANOVA, Bonferroni post-analysis. B, Western blotting analysis of VEGFR-2 and VEGFR-3 expression in lung, neonatal dermis and prostate LECs. beta -tubulin was used as a loading control. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/22745786), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human VEGFR3/Flt-4 Antibody

Application
Recommended Usage

Immunohistochemistry

5-15 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human lung and human cervical squamous metaplasia

Western Blot

0.1 µg/mL
Sample: Recombinant Human VEGFR3/Flt‑4 Fc Chimera (Catalog # 349-F4)

Reviewed Applications

Read 1 review rated 5 using AF349 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGFR3/Flt-4

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGFR3 (Flt-4). VEGFR3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGFR3 may be important for lymph angiogenesis.

References

  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Long Name

Vascular Endothelial Growth Factor Receptor 3

Alternate Names

Flt-4, FLT4, VEGF R3

Entrez Gene IDs

2324 (Human); 14257 (Mouse)

Gene Symbol

FLT4

UniProt

P35916

Additional VEGFR3/Flt-4 Products

Product Documents for Human VEGFR3/Flt-4 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human VEGFR3/Flt-4 Antibody

For research use only

Citations for Human VEGFR3/Flt-4 Antibody

Customer Reviews for Human VEGFR3/Flt-4 Antibody (1)

5 out of 5
1 Customer Rating
5 Stars
100%
4 Stars
0%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used Human VEGFR3/Flt-4 Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Customer Images

Showing  1 - 1 of 1 review Showing All
Filter By:
Clear Filters X
  • Human VEGFR3/Flt-4 Antibody
    Name: Anonymous
    Application: Western Blot
    Sample Tested: HUVEC human umbilical vein endothelial cells
    Species: Human
    Verified Customer | Posted 01/06/2026
    Works well in WB and ELISA
    Human VEGFR3/Flt-4 Antibody AF349

There are no reviews that match your criteria.

Showing  1 - 1 of 1 review Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies